Effect of Today's Deadline, Market Dynamics to Consider - Research Report on Jazz Pharmaceuticals, Inc. and Forest Laboratori...
August 02 2011 - 9:00AM
Marketwired
Today, www.EquityMarketsInc.com announced its research report
highlighting Jazz Pharmaceuticals, Inc. (NASDAQ: JAZZ) and Forest
Laboratories, Inc. (NYSE: FRX). Full content and research is
available at www.EquityMarketsInc.com/research.php.
Top considerations within today's market lie with the U.S.
Senate's ability to ratify a U.S. debt ceiling increase. Despite
the US National Gross Domestic Product beginning to move beyond
high-watermark, marking a significant shift away from recessionary
pressures, continued momentum relies upon inking of the most recent
tentative non-default agreement within senate before midnight
tonight. The US Department of Commerce has confirmed growth within
first quarter 2011, opening the strong possibility of companies
within sub-sectors to experience organic revenue growth in the case
of successful agreement.
No matter the outcome, opportunity is being marked for investors
to take advantage of equities with high-margin and specialty
products. Fundamental positives in this area are provided by
limited exposure to rising commodity costs. Although raw material
cost increases will continue to pressure margins, well-positioned
companies can leverage organic growth and general consolidation of
product lines to sustain bottom-line growth. Market-wise investors
are looking to build strong cash positions to take advantage of
events in the coming weeks, carefully watching for value within
equities boasting established pipelines and excellent growth
prospects.
Equity Markets has reviewed Jazz Pharmaceuticals, Inc. as a
specialty pharmaceutical company focusing on the development and
commercialization of pharmaceutical products to meet unmet medical
needs in neurology and psychiatry. The full research report on Jazz
Pharmaceuticals, Inc. (NASDAQ: JAZZ) is available here:
www.EquityMarketsInc.com/researchfile4634.php.
Equity Markets is covering Forest Laboratories, Inc. as a
company that develops, manufactures and sells branded forms of
ethical drug products, most of which requires a physician's
prescription. The Company also focuses on the development and
introduction of new products, including products developed in
collaboration with licensing partners. The full research report on
Forest Laboratories, Inc. (NYSE: FRX) is available here:
www.EquityMarketsInc.com/researchfile4891.php.
About Equity Markets Our mission at Equity Markets is to be the
best source of content and research, while educating, enlightening
and informing investors. Equity Markets combines street smart
analysts and professional market researchers to provide investors
with detailed company profiles and market coverage.
Contact: Samuel Littman Email Contact
www.EquityMarketsInc.com
Forest Road Acquisition (NYSE:FRX)
Historical Stock Chart
From Jun 2024 to Jul 2024
Forest Road Acquisition (NYSE:FRX)
Historical Stock Chart
From Jul 2023 to Jul 2024